LD 500 Introduction Goes Well

Contact: Stephen L. Davis

President and Chief Executive Officer

801-977-8970

www.paradigm-medical.com

FOR IMMEDIATE RELEASE

Paradigm Moves Ahead With LD500 Upgrade/Paramax  

SALT LAKE CITY, UT, March 18, 2011 Paradigm announced its Model LD 500 upgraded Autoperimeter received very positive responses from many of its existing customers. Since recently completing the long-awaited LD 400 upgrade, Paradigm has received substantial requests for this LD 500 model upgrade. During the past ten years, many LD 400 Autoperimeters were sold throughout the world. As a result of these past sales, there are a large number of systems that can be upgraded to the new LD 500 level at a very reasonable cost. These upgrades will be managed directly by Paradigm in the US and through its distributors in the international market. Paradigm anticipates a rapidly growing number of new upgrade orders in the upcoming months.

Paradigm recently received new updated information concerning the Retimax™ (Paramax™) from Costruzione Strumenti Oftalmici (CSO). Paradigm was told that the Food and Drug Administration (FDA) has requested additional information from them and approved an extension to CSO to provide this additional information. The first portions of the requested information have been sent and CSO stated, “They will complete the remaining information soon and forward it on to the FDA upon its completion.”

Paradigm President and Chief Executive Officer, Stephen Davis stated, “Paradigm remains confident that the FDA will recognize the benefits of this new technology and approve this beneficial device for the early detection of glaucoma.” He commented, “Paradigm will continue to monitor the evaluations of this important new device by key glaucoma specialists in the US market while it awaits a decision from the FDA.”

 About Paradigm Medical Industries, Inc.

Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes ophthalmic diagnostic instruments and related products for early detection of glaucoma and other eye disorders. The Company’s primary objective is to capture a niche market within the glaucoma and ultrasound microscopy fields. The Company markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States and internationally.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.